CCNA2 and neoplasm: Numerous genes that are involved in cell cycle were inhibited to downregulate in SARC by Comp1 and Comp2 treatments, especially CDK2 and CCNA2. Both CDK2 and CCNA2 are involved in tumor immunity and are significantly associated with disease-free survival in SARC.